Ramanbhai Foundation 1st International Symposium

"Current trends in Pharmaceutical sciences: Drug Discovery - Journey from Mouse to Man"

Day I: Thursday : 23rd January, 2003
8.00 – 9.00 hr   Registration

9.00 – 9.15 hr   Inauguration

9.20 – 10.20 hr  

Welcome Address - Towards new research initiatives
Mr. Pankaj R. Patel,
Chairman & Managing Director, Zydus Cadila

Inaugural Address

Session I: Medicinal Chemistry
10.20 hr.
Click here to see Speaker's Profile

Key-Note Address
Role of PPAR’s in Metabolism and Cell Physiology
Prof Walter Wahli,
Institut de Biologie Animale, Université de Lausanne,

11.10 hr.   TEA BREAK
11.30 hr.

RXRs, PPARs and Metabolic Diseases
Dr. Ranjan Mukherjee,
Senior Research Investigator, Bristol-Myers Squibb Co.,
Wilmington, USA

12.15 hr.

Development of Medicines Concerning Renin-Angiotensin System at Sankyo
Dr. Hiroaki Yanagisawa
Director, Medicinal Chemistry Research Laboratories,
Sankyo Co., Ltd., Japan

13.00 – 14.00 hr   LUNCH BREAK
14.00 hr A New Paradigm of Drug Discovery for the Twenty-First Century
Dr. Peter Lawrence Bullock,
Purdue Pharma LP, Ardsley,
New York , USA

14.45 hr

The Control of Acid Secretion by Proton Pump Inhibitors – An Ongoing Success Story of Tailored Molecules
Dr. Volker Figala
Vice President; Preclinical Development, Altana Pharma AG Byk-Gulden, Germany
15.30 hr

Novel Synthetic Methods for Fluorine - Containing Molecules
Prof. Tamejiro Hiyama
Department of Chemistry,
Kyoto University, Japan
16.15 hr - 17.15 hr   TEA BREAK and POSTER SESSION
17.15 hr

Drug-DNA interactions : Microcalorimetry and Spectroscopy
Dr. C. Vijaya Kumar
Professor of Chemistry, Physical and Biological Chemistry,
University of Connecticut, USA

18.00 hr

Human Genome and DNA Technology
Dr. Pradeep Kumar Srivastava
CDRI, Lucknow, India

19.00 hr   Cultural Programme
20.00 hr   DINNER

Day II : Friday : 24th January, 2003

Session II: Separation Technology

08.30 hr

The Use of Enantioselective Chromatography In Drug Discovery and Drug Development
Professor Irving W. Wainer
Director, Drug Discovery and Bioanalytical Chemistry Laboratory, Laboratory of Clinical Investigation,
National Institute on Aging / National Institutes of Health, USA
09.15 hr
Chiral Resolution: Past, Present & Future
Dr William John Lough
Reader in Pharmaceutical Analysis,
Institute of Pharmacy, Chemistry & Biomedical Sciences,
University of Sunderland, UK.
10.00 hr Capillary Electrophoresis, Chiral Separation in Pharmaceutical Analysis
Dr. David Llyod
Principal Scientist, Analytical R&D, Bristol Myers Squibb, Wilmington, USA
10.45 hr - 11.00 hr   TEA BREAK
11.00 hr Preparative Chromatographic Separation of Enantiomers
Dr. Eric R. Francotte
Head Separation & Cold Metabolism,
Novartis Pharma AG, Research Department, Central Technologies,
Basel, Switzerland.
Session III: Pre-clinical / Clinical Development of NCE’s
11.45 hr

Trends in Pre-Clinical Research
Dr. Oppel Greeff
Quintiles Transnational Corp., USA
12.30 hr

Evolving Paradigms of Preclinical Drug Development Processes: Bridging the Gap Between Discovery and Clinical Development
Dr Subrahmanyam Vangala

Site Head, Preclinical Pharmacokinetics, Johnson and Johnson Pharmaceutical
Research and Development, USA
13.15 hr -14.00 hr   LUNCH
14.00 hr
Clinical Trial Designs to Facilitate Pre-clinical to Clinical Transition in Drug Development
Dr. Darrell R. Abernethy
Chief, Laboratory of Clinical Investigation,
National Institute on Aging/ National Institutes of Health, USA
14.45 hr

Optimising Drug Development in Phase I/IIa
Prof. Dr. Monika Seibert-Grafe
Board Certified Anaesthesiologist and Clinical Pharmacologist,
Head of Coordination Centre for Clinical Trials, University Hospital
Heidelberg, Germany
15.30 hr

Project Management in Clinical Drug Development
Dr. Heinz W. Radtke
Executive Vice-President, Research and Development, Byk-Gulden, Altana Pharma, Germany
16.15 hr   TEA BREAK
Session IV: Patents, ICH Guidelines & Business Development
16.45 hr
International Harmonisation and Overview – ICH
Dr. Fritz Erni
Head Novartis Pharmanalytica SA,
Locarno, Switzerland
17.30 hr
Implications of the Changing Patent Regime and Patent Litigations in Pharma
Mr. S. Majumdar
Patent Attorney, S. Majumdar & Company,
Kolkata, India
18.15 hr   Flexibility in Partnering, Becoming a Preferred Partner
Dr. Ravi Sodha
Business Licensing and Development, Head, Scientific Evaluation,
Novartis Pharma AG
19.00 hr   Concluding Session
19.20 – 21.00 hr   ZRC Anniversary Celebrations followed by Dinner



Home Contact Us